DNA vaccination in utero: a new approach to induce protective immunity in the newborn
Introduction
Early life infections with pathogens such as herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis B virus (HBV), group B Streptococcus sp. (GBS), Haemophilus sp. or Chlamydia sp. are responsible for significant morbidity and mortality in large numbers of human infants every year (reviewed in [1], [2]). Disease transmission from mother to infant frequently occurs shortly before, during or after birth by early rupture of the amniotic membranes or direct contact with infectious secretions during labor. Infections can also result from non-sterile delivery techniques, by breast feeding or during the first days of life in a perinatal nursery. To reduce the risk of infection, improved neonatal care together with caesarian sections, antibiotic treatments, and maternal antiviral therapy are currently being used to prevent vertical disease transmission. However, there is a significant need for alternative therapeutic approaches to prevent neonatal infection.
Vaccination has provided a very cost-effective approach to prevent infectious diseases. However, the induction of tolerance or a state of non-responsiveness was previously thought to preclude vaccination as an effective therapy in the fetus or newborn [3]. We recently demonstrated that DNA immunization in utero induced strong immunity in fetal lambs when delivered into the oral cavity into the amniotic fluid at days 120–125 of gestation [4], [5] (gestation period of sheep is 145 days). Strong humoral and cell-mediated immune responses were found in all immunized fetuses following a single administration of 500 μg plasmid DNA encoding the truncated version of glycoprotein gD of bovine herpesvirus-1 (BHV-1). Additionally, antigen (Ag)-specific antibody-secreting cells were found in the retropharyngeal lymph node draining the oral cavity. Thus, we showed for the first time that in utero immunization with plasmid DNA induces strong immunity in the fetus, which could have a significant impact on survival and quality of life for the large number of infants infected during or shortly after birth [4], [5]. However, since manipulations in utero could result in abortions or fetal misdevelopment, we addressed the safety of in utero DNA vaccination by analyzing fetal development, neonatal viability and development of the neonatal immune system.
Fetal lambs represent a valuable model for analyzing in utero vaccination because of a number of physiological similarities between the ovine and human fetal development and the ontogeny of their immune systems. Using fetal lambs we confirmed observations in higher primates where fetal immunization with a recombinant protein vaccine induced active immunity in the newborn [6]. Three in utero immunizations with a hepatitis B (HB) vaccine induced detectable immune responses in 75% (5/8) of newborn baboons [6]. Thus, these observations verify that the last term fetus is fully immunocompetent and that in utero immunization may represent a useful approach to prevent vertical disease transmission in diseased pregnant women. Vertical disease transmission occurs primarily through mucosal surfaces and we therefore analyzed the induction of mucosal immunity and immune memory in the newborn by in utero immunization which would significantly enhance disease protection in the neonate. To identify the sites of uptake and expression of the plasmid DNA we used luciferase encoding plasmid DNA for in utero delivery and analyzed local expression within the oral cavity and other mucosal sites. Neonatal immune memory was addressed by analyzing immune responses to either a secondary DNA vaccination or a viral infection within the first 10 days after birth. Moreover, immune protection against a respiratory viral infection was assessed in an experimental challenge with infectious BHV-1. To compare the efficacy of fetal DNA immunization with a licensed protein vaccine, we analyzed the induction of protective immunity against HBV, an important pathogen of newborn infants (reviewed in [7], [8]) following fetal immunization with either a HBV surface antigen (HBsAg) protein or DNA vaccine.
Section snippets
Cells, viruses, plasmids
Bovine viral diarrhea virus-free Madin Darby bovine kidney (MDBK) cells were cultured in minimum essential medium (MEM; Gibco-BRL, Burlington, Ont., Canada) supplemented with 5% fetal bovine serum (FBS; Gibco-BRL). BHV-1 strain 108, is a virulent field isolate [9] and was propagated in MDBK cells. Plasmid pSLIA-tgD [10] encoding the truncated version of glycoprotein D (tgD) of BHV-1 under the control of the human CMV immediate early promotor/1A region was kindly provided by Drs. Ralph Braun and
Efficacy and safety of in utero DNA vaccination
We previously reported that oral DNA immunization in utero induced BHV-1 gD-specific immune responses in immunized fetal lambs [4], [5]. Summarizing the data from three independent experiments, we show here that high levels of gD-specific serum antibody titers and lymphoproliferative responses in the blood were found in more than 80% of DNA-immunized fetuses (16/19, DNA, Fig. 1). In contrast, gD-specific immune systemic immune responses were not found in PBS-treated animals (0/15, control).
Discussion
Infectious diseases are the primary cause for high morbidity and mortality rates in newborns of most species (reviewed in [1], [2]). Maternal immunoglobulin and other factors in milk, such as complement components and soluble CD14, provide some disease protection in the neonate [16], [17], but this is not sufficient to protect against many infectious diseases. Thus, vaccination is an attractive approach to enhance disease protection in the neonate. There is increasing evidence that neonates of
Acknowledgements
Research funding was provided by the Canadian Institutes of Health Research and Alberta Agriculture Research Institute, and the Deutsche Forschungsgemeinschaft (DFG, Ge 1039/1-2). Article published with permission of the Director of VIDO as article # 350.
References (43)
- et al.
Infectious diseases in early life in industrialized countries
Vaccine
(1998) Serious infections in young infants in developing countries
Vaccine
(1998)- et al.
DNA immunization of infants: potential and limitations
Vaccine
(1998) Dendritic cell migration to lymph nodes: cytokines, chemokines and lipid mediators
Sem. Immunol.
(2001)- et al.
Vaccine induced immunological memory for hepatitis B surface antigen: implications for policy on booster vaccination
Vaccine
(1996) - et al.
Enhanced protection against influenza virus of mice immunized as newborns with a mixture of plasmids expressing hemagglutinin and nucleoprotein
Vaccine
(1998) - et al.
Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus
Vaccine
(1997) - et al.
Induction of immunological memory in baboons primed with DNA vaccine as neonates
Vaccine
(2001) - et al.
Immune response to neonatal genetic immunization
Virology
(1997) - et al.
Induction of cytotoxic T cell responses in newborn mice by DNA immunization
Vaccine
(1997)
Regulation of T cell homeostasis during fetal and early postnatal life
Vet. Immunol. Immunopathol.
From A to Z on CpG
Trends Immunol.
Fetal immunization by a DNA vaccine delivered into the oral cavity
Nat. Med.
Oral DNA vaccination in utero induces mucosal immunity and immune memory in the neonate
J. Immunol.
Fetal immunization of baboons induces a fetal-specific antibody response
Nat. Med.
Overview of the pathogenesis, prophylaxis and therapeutics of viral hepatitis B, with focus on reduction to practical applications
Vaccine
Response of the respiratory tract of calves kept at controlled climatic conditions to bovine herpesvirus 1 in aerosol
Can. J. Comp. Med.
Enhanced immune response to an intradermally derived DNA vaccine expressing a secreted form of BHV-1 gD
Vaccine Res.
Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice
Hum. Gene Ther.
Cited by (7)
Animal models for neonatal diseases in humans
2013, VaccineCitation Excerpt :Models for these infections include small rodents such as mice, non-human primates, pigs and sheep. For example, an in utero model was used in pigs and sheep to assess the potential of vaccination to control transmission at birth or during breastfeeding [61,62]. For Dengue virus non-human primates and mice remain the most commonly used model [63–66], humanized or immunosuppressed mice are a good alternative [67].
Maternal-fetal transmission of HBV
2012, Maternal Fetal Transmission of Human Viruses and their Influence on TumorigenesisVaccination in pregnancy
2011, Current Pharmaceutical BiotechnologyDNA vaccination against herpesvirus
2011, DNA Vaccines: Types, Advantages and LimitationsConstruction of sperm-specific lactate dehydrogenase DNA vaccine and experimental study of its immunocontraceptive effect on mice
2008, Science in China, Series C: Life Sciences